The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
| Autor: | C.G.J. Sweep, T. H. Van Tienoven, Louk V.A.M. Beex, J.A. Foekens, J. Geurts-Moespot, Peggy Manders, V.C.G. Tjan-Heijnen |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Vascular Endothelial Growth Factor A Oncology Cancer Research medicine.medical_specialty Pathology Time Factors Angiogenesis medicine.medical_treatment Breast Neoplasms Endothelial Growth Factors Disease node-negative breast cancer Systemic therapy angiogenesis Experimental diagnostics and therapy of malignancies chemistry.chemical_compound Breast cancer Internal medicine Progesterone receptor medicine Humans prognostic value Survival rate Aged Neoplasm Staging Proportional Hazards Models Chemical Endocrinology Lymphokines vascular endothelial growth factor Sentinel Lymph Node Biopsy Vascular Endothelial Growth Factors business.industry Age Factors Molecular and Cellular Pathology Middle Aged Prognosis medicine.disease Survival Analysis Vascular endothelial growth factor chemistry Chemotherapy Adjuvant Intercellular Signaling Peptides and Proteins Female Neoplasm Recurrence Local business Adjuvant |
| Zdroj: | British Journal of Cancer, 87, 7, pp. 772-8 British Journal of Cancer, 87, 772-8 British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | The growth and metastasising capacity of solid tumours are dependent on angiogenesis. Vascular endothelial growth factor is a mediator of angiogenesis. In this study we investigated whether vascular endothelial growth factor is associated with the natural course of the disease in primary invasive breast cancer. In 574 tumours of patients with node-negative invasive breast cancer the cytosolic levels of vascular endothelial growth factor were measured using a quantitative enzyme-linked immunosorbent assay. These patients did not receive adjuvant systemic therapy and were followed for a median follow-up time of 61 months (range 2–155 months) after the primary diagnosis. Correlations with well-known prognostic factors, and univariate and multivariate survival analyses were performed. Vascular endothelial growth factor level was positively associated with age and tumour size (P=0.042 and P=0.029, respectively). In addition, vascular endothelial growth factor level was inversely, but weakly correlated with progesterone receptor levels (PgR) (rs=−0.090, P=0.035). A high vascular endothelial growth factor level (equal or above the median level of 0.53 ng mg−1 protein) predicted a reduced relapse-free survival and overall survival in the univariate survival rate analysis (for both P=0.005). In the multivariate analysis as well, vascular endothelial growth factor showed to be an independent predictor of poor relapse-free survival and overall survival (P=0.045 and P=0.029, respectively), in addition to age, tumour size and PgR. The results show that cytosolic levels of vascular endothelial growth factor in tumour tissue samples are independently indicative of prognosis for patients with node-negative breast cancer who were not treated with adjuvant systemic therapy. This implies that vascular endothelial growth factor is related with the natural course of breast cancer progression. British Journal of Cancer (2002) 87, 772–778. doi:10.1038/sj.bjc.6600555 www.bjcancer.com © 2002 Cancer Research UK |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|